Key Highlights

  • Record third-quarter Revenue of USD 313 million rose 13% year over year, or 19% excluding a one-time benefit from a commercial Partnership recorded in the 2025 quarter.
  • Operating margin was 32.2% and adjusted EBITDA (non-GAAP) was USD 111 million, or 35.5% of revenue, up 1,060 basis points from a year earlier.
  • GAAP Net Income was USD 0.50 per diluted share against USD 0.10, while adjusted diluted EPS (non-GAAP) was USD 0.53, up 61% year over year.
  • Full-year 2026 revenue guidance rose to USD 1,143 million to USD 1,163 million from USD 1,130 million to USD 1,150 million, and adjusted EPS guidance to USD 1.68 to USD 1.72.

Record Quarter Led by Broad End-Market Strength

Cognex (NASDAQ:CGNX) reported results for the quarter ended October 4, 2026 on November 4, 2026. Revenue of USD 313 million compared with USD 277 million as reported and USD 264 million excluding the one-time commercial partnership benefit in the third quarter of 2025. Management said strength was broad across most major end markets, and currency had no meaningful effect. Gross margin was 70.8% against 67.6%, and adjusted gross margin was 71.3% against 68.4%, helped by mix, Volume and faster-than-expected pricing, which more than offset expected memory cost headwinds. Operating expenses fell 7% to USD 121 million, and Operating Income reached USD 101 million versus USD 58 million as reported.

Profit Surge Against a Distorted Comparison

GAAP net income was USD 85 million versus USD 18 million, while adjusted net income was USD 90 million versus USD 56 million. The year-ago quarter is distorted by the commercial partnership with a medical lab automation channel partner, so excluding it adjusted EPS rose 89% from USD 0.28. The CFO described adjusted EBITDA flow-through as above 100%, and the company called this the ninth consecutive quarter of adjusted EPS growth and margin expansion. Cognex had USD 846 million of cash and investments and no debt, generated USD 106 million of Operating Cash Flow and USD 104 million of free cash flow, and paid USD 14 million in dividends. Free cash flow was 122% of net income for the quarter, according to the release. The board declared a quarterly Dividend of USD 0.09 per share, up about 6%, payable December 3, 2026.

Higher Guidance and the RealSense Deal

Fourth-quarter guidance calls for revenue of USD 270 million to USD 290 million, adjusted EBITDA margin of 29% to 32% and adjusted EPS of USD 0.37 to USD 0.41. The full-year adjusted EBITDA margin range moved to 31% to 32% from 29% to 31%. Separately, Cognex (NASDAQ:CGNX) agreed to buy RealSense, a supplier of depth-sensing cameras for robotic perception and physical artificial intelligence, in an all-cash deal expected to close in the fourth quarter of 2026. The price was not stated in the material reviewed. Risks include memory component costs, the one-time nature of last year's partnership gain and integration of the acquisition.

Where Things Stand

The margin looks well supported for now, though the comparison is flattering. Cognex (NASDAQ:CGNX) converted 13% revenue growth into a 32.2% Operating Margin through pricing, mix and lower expenses, and management raised full-year guidance and its dividend. Part of the profit growth reflects a weak base, since the year-ago quarter included a partnership item. Memory costs were a headwind in the quarter, and the fourth-quarter adjusted EBITDA margin guidance of 29% to 32% is below the third-quarter 35.5%. Next markers are RealSense closing and fourth-quarter delivery against the guidance range.